

TRAC: **TFORD** RETROSPECTIVE ANALYSIS FOR COVID-19

RETROSPECTIVE ASSESSMENT OF TREATMENTS OF HOSPITALIZED COVID-19 PATIENTS

TFORD-COVID-19

The Principal Scientific Advisor to the Government of India, Dr. Vijay Raghavan, has constituted a [Task Force on Repurposing of Drugs for COVID19](#) (TFORD-COVID-19). The advisory group of this task force has been reviewing evidence on repurposed drugs for use in India. After much deliberation it was felt that there is need to study the outcome of the therapeutic modalities in use currently, using a retrospective study design.

Rationale for TRAC Study

Retrospective study data helps form hypotheses regarding efficacy and safety of therapeutic interventions. Such hypotheses help in designing randomized clinical trials which are the gold standard for establishing safety and efficacy of interventions. Under the current pandemic situation, patients in India are being treated using different therapeutic agents/procedures. There is need to identify which of the current interventions are really useful and which are not, so that an evidence based policy can be developed.

TRAC Study Details

In the TRAC study, we plan to collect data on demographics, treatments used and outcomes of patients admitted with RT PCR positive (for Covid 19). The data will be collected only of those patients who have been discharged or have passed away at different hospitals in Pune. We plan to collect the maximal available data, which will be analyzed using advanced techniques to evaluate outcomes of interventions used. Subsequently, the group will decide whether the study needs to be replicated in other parts of the country.

Current Status of TRAC Study

A protocol has been prepared and the Ethics Committee approval obtained. The study has been registered on the Indian Clinical Trial Registry (CTRI). This is a non-interventional study, and poses no risk to any patient or volunteer. Data collection will comply with international principles for protecting privacy and confidentiality. , Data collected shall remain the property of the participating hospital, and the group will only use anonymized data for analysis.

For further details , please visit

<https://nclinnovations.org/covid19/trac/>